Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | John Strickler: ESMO 2019 Highlights

John Strickler • 30 Sep 2019
ESMO 2019
Gastrointestinal Cancer Pembrolizumab
KEYNOTE-062

John Strickler, MD, Duke Cancer Center, Durham, NC, gives his ESMO 2019 highlights, specifically mentioning key trial insights such as updates in the KEYNOTE-062 study (NCT02494583). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from John Strickler

1:25
Real-world treatment patterns for HER2-amplified colorectal cancer
John Strickler • 21 Oct 2023
0:44
Using ctDNA to identify mutations in colorectal cancer
John Strickler • 21 Oct 2023
0:58
MOUNTAINEER: clinical relevance of genomic profiling for tucatinib + trastuzumab treatment in mCRC
John Strickler • 21 Oct 2023
2:28
MOUNTAINEER: impact of genomic alterations on tucatinib plus trastuzumab activity in mCRC
John Strickler • 21 Oct 2023

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals